retatrutide trial results Shows Promising in Type 2 Diabetes and Obesity | Michael Weintraub, MD posted on the topic Retatrutide Shows 28% Weight Loss

The differences in the metabolic pathways are also expressed in the therapeutic doses, which may range from 5 mg for saxagliptin to 100 mg for sitagliptin, and in the dosing frequency

your daily choices determine how far you go with it

"Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022 (SURMOUNT-1) ClinicalTrials.gov: TRIUMPH Phase 3 program trial protocols and status updates FDA Prescribing Information: Wegovy, Mounjaro/Zepbound, Saxenda (for comparative safety data) Frequently Asked Questions Most side effects peak during dose escalation (weeks 412) and improve substantially by week 24

Oral pill, easier to take

Then they can eat more normally as the week progresses and the medication effect moderates

53 In both Phase 1a and 1b trials, it has been established that orforglipron does not have food or water administration restrictions and may provide a safe and effective oral treatment option for patients with T2D and other indications